Page 3 - Antipsychotics News Today

Higher doses of a second-generation antipsychotic are associated with an increased risk of dying in young adults aged 18-24 years, results of a large retrospective cohort study showed.

The lifespan of schizophrenia patients is significantly shorter than the general population. Olanzapine is one of the most commonly used antipsychotic drugs (APDs) for treating patients with psychosis, including schizophrenia and bipolar disorder. Despite their effectiveness in treating positive and negative symptoms, prolonged exposure to APDs may lead to accelerated aging and cognitive decline, among other side effects. Here we report that dysfunctional mitophagy is a fundamental mechanism und...

Real-world primary care data indicate that use of antipsychotics and antibiotics, among other meds, can significantly increase the risk of sudden cardiac arrest among people with type 2 diabetes.

Sanjai Rao, MD, shared best practices for utilizing long-acting injectable antipsychotics at the 2023 Psychiatric Times World CME Conference.

While use of atypical antipsychotics is rising, a new study found that the drugs are not safer than haloperidol for managing postoperative delirium in elderly patients.

Long-term results still show higher mortality among patients with schizophrenia vs the general population. Substance use is a main predictor of mortality, and suicide accounted for 27.5% of all deaths.

The agency defended approval of brexpiprazole (Rexulti) for the treatment of agitation, saying the antipsychotic fills an unmet medical need.

By Natalie Matosin, Jess Nithianantharajah, Brian Dean, et al., Published on 01/01/23

Are the antipsychotics. medications that can increase their probability to -- they can kill them. >> the doctor gave us medicine for him, but he start to be like a zombie. >> reporter: she had an idea for older patients like joseph based upon what she had seen with some of the youngest. >> when i saw that ka nan boyds are approved for epilepsy and children, i thought, if it can help here, they might help in the behavioral disturbances of dementia. >> reporter: it was a simple theory. during a se...

1. For patients with schizophrenia, symptomatic response to antipsychotic medication at 2 and 4 weeks after initiation can appropriately predict non-response at 8 weeks, varying by baseline severity and specific antipsychotic trialed. Evidence Rating Level: 1 (Excellent) For patients with schizophrenia trialed on antipsychotic medication, it is unclear when to switch medication for failed responses,